New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling

Biochemical Pharmacology

Volumn 93, Issue 1, 2015, Pages 85-91

  Brust, Tarsis F ^a   Hayes, Michael P ^b   Roman, David L ^b   Watts, Val J ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Aripiprazole; Dopamine; Functional selectivity; Gbetagamma; GPCR

Indexed keywords

ADENYLATE CYCLASE; ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; GI PROTEIN BETA GAMMA SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; HALOPERIDOL; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SENSITIZATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; PHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEIN BETA SUBUNITS; GTP-BINDING PROTEIN GAMMA SUBUNITS; HALOPERIDOL; HEK293 CELLS; HUMANS; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION;

EID: 84919722766     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.10.014     Document Type: Article

References (47)

1. Urban J, Clarke W, von Zastrow M, Nichols D, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320:1-13.
2. Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 2013;12:205-16.
3. Whalen E, Rajagopal S, Lefkowitz R. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 2011;17:126-39.
4. Beaulieu J, Gainetdinov R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011;63:182-217.
5. Watts V, Neve K. Sensitization of adenylate cyclase by Galphai/o-coupled receptors. Pharmacol Ther 2005;106(3):405-21.
6. Meissner W, Frasier M, Gasser T, Goetz C, Lozano A, Piccini P, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10:377-93.
7. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3.
8. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008;60:358-403.
9. Mailman R, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity. Curr Pharm Des 2010;16:488-501.
10. Jones M, White J, Gray R. Partial agonists and schizophrenia: theoretical developments for the development of mental health nursing. J Psychiatr Ment Health Nurs 2009;16:409-15.
11. Allen J, Yost J, Setola V, Chen X, Sassano M, Chen M, et al. Discovery of beta-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proc Natl Acad Sci USA 2011;108:18488-93.
12. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9.
13. Fell MJ, Perry KW, Falcone JF, Johnson BG, Barth VN, Rash KS, et al. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268). J Pharmacol Exp Ther 2009;331:1126-36.
14. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11.
15. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007;32:67-77.
16. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612-27.
17. Cooper D, Crossthwaite A. Higher-order organization and regulation of adenylyl cyclases. Trends Pharmacol Sci 2006;27:426-31.
18. Watts VJ, Neve KA. Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. Mol Pharmacol 1997;52:181-6.
19. Federman AD, Conklin BR, Schrader KA, Reed RR, Bourne HR. Hormonal-stimulation of adenylyl cyclase through gi-protein beta-gamma-subunits. Nature 1992;356:159-61.
20. Chern Y. Regulation of adenylyl cyclase in the central nervous system. Cell Signal 2000;12:195-204.
21. Lee KW, Hong JH, Choi IY, Che Y, Lee JK, Yang SD, et al. Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J Neurosci 2002;22:7931-40.
22. Schroder R, Schmidt J, Blattermann S, Peters L, Janssen N, Grundmann M, et al. Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc 2011;6:1748-60.
23. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Therap 2004;26:649-66.
24. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011;25:109-27.
25. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
26. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002;1:141-7.
27. Harrison C, Traynor JR. The [35S]GTPgammaS binding assay: approaches and applications in pharmacology. Life Sci 2003;74:489-508.
28. Luscher C, Slesinger PA. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat Rev Neurosci 2010;11:301-15.
29. Chester JA, Mullins AJ, Nguyen CH, Watts VJ, Meisel RL. Repeated quinpirole treatments produce neurochemical sensitization and associated behavioral changes in female hamsters. Psychopharmacology 2006;188:53-62.
30. Culm KE, Lugo-Escobar N, Hope BT, Hammer Jr RP. Repeated quinpirole treatment increases cAMP-dependent protein kinase activity and CREB phosphorylation in nucleus accumbens and reverses quinpirole-induced sensorimotor gating deficits in rats. Neuropsychopharmacology 2004;29:1823-30.
31. Bach ME, Simpson EH, Kahn L, Marshall JJ, Kandel ER, Kellendonk C. Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning. Proc Natl Acad Sci USA 2008;105:16027-32.
32. Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006;49:603-15.
33. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006;60:319-46.
34. Kerwin RW, Beats BC. Increased forskolin binding in the left parahippocampal gyrus and CA1 region in post mortem schizophrenic brain determined by quantitative autoradiography. Neurosci Lett 1990;118:164-8.
35. Muly C. Signal transduction abnormalities in schizophrenia: the cAMP system. Psychopharmacol Bull 2002;36:92-105.
36. Ferrie AM, Sun H, Zaytseva N, Fang Y. Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed beta(2)-adrenergic receptors. Sci Rep 2014;4:3828.
37. Schroder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 2010;28:943-9.
38. Kenakin T. What is pharmacological 'affinity'? Relevance to biased agonism and antagonism. Trends Pharmacol Sci 2014.
39. Beaulieu J, Tirotta E, Sotnikova T, Masri B, Salahpour A, Gainetdinov R, et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 2007;27:881-5.
40. Del'guidice T, Lemasson M, Beaulieu J. Role of Beta-arrestin 2 downstream of dopamine receptors in the Basal Ganglia. Front Neuroanat 2011;5:58.
41. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu J, Gainetdinov R, et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 2008; 105:13656-61.
42. Beaulieu J, Marion S, Rodriguiz R, Medvedev I, Sotnikova T, Ghisi V, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 2008;132:125-36.
43. Beaulieu J, Sotnikova T, Marion S, Lefkowitz R, Gainetdinov R. Caron M. An Akt/ beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005;122:261-73.
44. Urs NM, Snyder JC, Jacobsen JP, Peterson SM, Caron MG. Deletion of GSK3beta in D2R-expressing neurons reveals distinct roles for beta-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci USA 2012;109:20732-37.
45. Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, et al. Structurefunctional selectivity relationship studies of beta-arrestin-biased dopamine D(2) receptor agonists. J Med Chem 2012;55:7141-53.
46. Khan SM, Sleno R, Gora S, Zylbergold P, Laverdure JP, Labbe JC, et al. The expanding roles of Gbetagamma subunits in G protein-coupled receptor signaling and drug action. Pharmacol Rev 2013;65:545-77.
47. Lin Y, Smrcka AV. Understanding molecular recognition by G protein beta-gamma subunits on the path to pharmacological targeting. Mol Pharmacol 2011;80:551-7.